Tranzyme Pharma Announces Third Quarter 2012 Financial Results

Published: Nov 09, 2012

RESEARCH TRIANGLE PARK, N.C, Nov. 8, 2012 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM), a biopharmaceutical company focused on discovering, developing and commercializing novel, first-in-class small molecule therapeutics for the treatment of gastrointestinal (GI) motility disorders, today announced its financial results and business update for the third quarter ended September 30, 2012.

Back to news